08:38 AM EST, 12/18/2025 (MT Newswires) -- CAMP4 Therapeutics ( CAMP ) said Thursday it has entered a research, collaboration and license agreement with GSK (GSK) to identify and develop antisense oligonucleotide drug candidates targeting neurodegenerative and kidney disease indications.

Under the agreement, CAMP4 Therapeutics ( CAMP ) will receive upfront cash payment of $17.5 million and is eligible for additional development and commercial milestone payments, as well as tiered royalties on future product sales, the company said.

The collaboration will use CAMP4 Therapeutics' ( CAMP ) RAP Platform to identify regulatory RNAs that control the expression of gene targets and generate ASO candidates, CAMP4 Therapeutics ( CAMP ) said.

GSK will be responsible for the further development and commercialization of any drug candidates from the collaboration, the company said.

Shares of CAMP4 Therapeutics ( CAMP ) were down 6%, while GSK shares were down 0.7% in recent Thursday premarket activity.